Zura Bio Limited (ZURA)

Market Cap	122.75M
Revenue (ttm)	n/a
Net Income (ttm)	-42.62M
Shares Out	65.29M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	395,663
Open	1.770
Previous Close	1.760
Day's Range	1.730 - 1.910
52-Week Range	1.600 - 6.350
Beta	0.04
Analysts	Buy
Price Target	15.80 (+740.43%)
Earnings Date	Mar 12, 2025

About ZURA

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2022
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: ZURA
• Website: https://zurabio.com

Analyst Forecast

According to 6 analysts, the average rating for ZURA stock is "Buy." The 12-month stock price forecast is $15.8, which is an increase of 740.43% from the latest price.

Price Target

$15.8

(740.43% upside)

Analyst Consensus: Buy